Deal Library / Pharma BD Deal Intelligence

Gilead Sciences Inc. — Pharma Deals

The Pharma Closeout tracks 14 deals, $77.7B in disclosed deal value, 12 with a post-close Outcome Score for Gilead Sciences Inc..

Median Critic Score: 84 · Median Outcome Score: 64

All 14 deals

Gilead Sciences Inc. / Pharmasset Inc. — 2011 · $11.2B · Worked — the deal delivered on its rationale.
Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. — 2002 · $464M · Worked — the deal delivered on its rationale.
Gilead Sciences Inc. / CymaBay Therapeutics — 2024 · $4.4B · Worked — the deal delivered on its rationale.
Gilead Sciences Inc. / Nurix Therapeutics Inc. — 2019 · $2.3B · Largely worked — most objectives met.
Gilead Sciences Inc. / Immunomedics Inc. — 2020 · $21.0B · Largely worked — most objectives met.
Gilead Sciences Inc. / Kite Pharma Inc. — 2017 · $11.9B · Largely worked — most objectives met.
Gilead Sciences Inc. / CV Therapeutics Inc. — 2009 · $1.4B · Largely worked — most objectives met.
Gilead Sciences Inc. / Myogen Inc. — 2006 · $2.5B · Largely worked — most objectives met.
Gilead Sciences Inc. / Arcus Biosciences, Inc. — 2020 · $5.0B · Mixed — partial payoff, real shortfalls.
Gilead Sciences Inc. / Goldfinch Bio Inc. — 2019 · $240M · Did not work — the deal failed to deliver.
Gilead Sciences Inc. / Galapagos NV — 2019 · $5.1B · Did not work — the deal failed to deliver.
Gilead Sciences Inc. / Forty Seven Inc. — 2020 · $4.9B · Did not work — the deal failed to deliver.
Gilead Sciences Inc. / Ouro Medicines, Inc. — 2026 · $2.2B
Gilead Sciences Inc. / Tubulis GmbH — 2026 · $5.0B